I guess I stated it incorrectly, or maybe it was read that way. I don't think GNBT not releasing info on the peptide progress has slowed down GNBT. However as you stated "2) if they don't come calling and GNBT develops a peptide vaccine that does well in trials, they WILL come calling" is the key. GNBT does not have to "releasing internal technological information that is proprietary to GNBT/NGIO" to anyone that does not sign a confidentiality agreement, however letting the world know we have a synthetic peptide, that will be a complete vaccine, will go thru human trials and billions of doses can be manufactured in a fraction of the time for a fraction of the cost, will help bring in those that we want to come calling.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.